Biohaven revealed in a filing with the Securities and Exchange Commission (SEC) that it has been updated on the progress of ...

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for ...

Biohaven (NYSE:BHVN) stock gains as the FDA cancels an advisory meeting scheduled to review its marketing application for ...

The latest announcement is out from Biohaven Ltd. ( (BHVN) ).

Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit.

Biohaven stock surged early Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug, ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...

Investing.com -- Biohaven Ltd. (NYSE: BHVN) stock rose 3% Friday morning after the company announced that the U.S. Food and Drug Administration (FDA) no longer plans to hold an advisory committee ...

In a report released on August 15, William Pickering from Bernstein maintained a Buy rating on Biohaven Ltd., with a price target of $34.00. The company’s shares closed last Friday at $15.71. Take ...

More bad news has come down for Biohaven’s small molecule troriluzole. | More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...